inv-202
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2022 (NCT05282446)
Timeline
Indications
Mechanism of action
- Cannabinoid CB1 receptorINVERSE AGONIST
CNR1 inverse agonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)NC(=N)/N=C(\NS(=O)(=O)c1ccc(C(F)(F)F)cc1)N1N=C(c2ccc(Cl)cc2)C[C@H]1c1ccccc1- Mol. weight
- 591.02 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314529 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06542536 | Phase 1 | Aug 9, 2024 | Novo Nordisk |
| NCT05891834 | Phase 2 | Sep 8, 2023 | Inversago Pharma Inc. |
| NCT05514548 | Phase 2 | Oct 19, 2022 | Inversago Pharma, Inversago Pharma Inc., Worldwide Clinical Trials |
| NCT05282446 | Phase 1 | Mar 1, 2022 | Inversago Pharma, Inversago Pharma Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Inversago Pharma Inc. | For profit | 3 | 3 | 2 | 2022 |
| Inversago Pharma | For profit | 2 | 0 | 2 | 2022 |
| Novo Nordisk | For profit | 1 | 1 | 1 | 2024 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1